

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 911 633 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
28.04.1999 Bulletin 1999/17

(51) Int. Cl.<sup>6</sup>: **G01N 33/50**, **G01N 33/566**

(21) Application number: **98203332.6**

(22) Date of filing: **02.10.1998**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **08.10.1997 US 61334 P**

(71) Applicant:  
**SMITHKLINE BEECHAM CORPORATION**  
**Philadelphia Pennsylvania 19103 (US)**

(72) Inventors:  
• **McDonnell, Peter C.,**  
**SmithKline Beecham Pharmaceu.**  
**King of Prussia, PA 19406 (US)**

• **Young, Peter R.,**  
**SmithKline Beecham Pharmaceutica.**  
**King of Prussia, PA 19406 (US)**  
• **Zou, Jun,**  
**SmithKline Beecham Pharmaceuticals**  
**King of Prussia, PA 19406 (US)**

(74) Representative:  
**Connell, Anthony Christopher et al**  
**SmithKline Beecham plc**  
**Corporate Intellectual Property,**  
**Two New Horizons Court**  
**Brentford, Middlesex TW8 9EP (GB)**

(54) **A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5**

(57) The present invention relates to tumor necrosis factor receptor (TNF-R) related polypeptides and their ligands, hereinafter referred to as TR1, TR3, TR5, and TL3. The invention relates to methods to identify agonists and antagonists of TR 1, TR3, TR5, and TL3.

**EP 0 911 633 A1**

## Description

## FIELD OF INVENTION

5 [0001] The present invention relates to tumor necrosis factor receptor (TNF-R) related polypeptides (proteins) and their ligands, hereinafter referred to as TR1, TR3, TR5, and TL3. The invention also relates to inhibiting or activating the action of such polypeptides using agonists or antagonists by the screening methods described herein.

## BACKGROUND OF THE INVENTION

10 [0002] Many biological actions are a response to certain stimuli and natural biological processes, and are controlled by factors, such as cytokines. These cytokines act through target cell receptors by engaging the receptor and producing an intracellular response.

15 [0003] For example, tumor necrosis factors (TNF) alpha and beta are cytokines which act through TNF receptors to regulate numerous biological processes, including protection against infection and induction of shock and inflammatory disease. The TNF molecules belong to the "TNF-ligand" superfamily, and act together with their receptors or counterligands, the "TNF-receptor" superfamily. So far, ten members of the TNF ligand superfamily have been identified and thirteen members of the TNF-receptor superfamily have been characterized.

20 [0004] Among the ligands there are included TNF-a, lymphotoxin-a (LT-a, also known as TNF-b), LT-b (found in complex heterotrimer LT-a2-b), FasL, CD40L, CD27L, CD30L, 4-1BBL, OX40L and TRAIL ((Wiley et al. Immunity 3:673-682 (1995)). All but one of these (LTa) are expressed as type II membrane proteins. The superfamily of TNF receptors includes the p55TNF receptor, p75TNF receptor, TNF receptor-related protein, FAS antigen or APO-1, CD40, CD27, CD30, 4-1BB, OX40, low affinity p75 ,NGF-receptor(Meager, A., Biologicals, 22:291-295 (1994)).

25 [0005] Many members of the TNF-ligand superfamily are expressed by activated T-cells, implying that they are necessary for T-cell interactions with other cell types which underlie cell ontogeny and functions. (Meager, A., supra).

30 [0006] Considerable insight into the essential functions of several members of the TNF receptor family has been gained from the identification and creation of mutants that abolish the expression of these proteins. For example, naturally occurring mutations in the FAS antigen and its ligand cause lymphoproliferative disease (Watanabe-Fukunaga, R., et al., Nature 356:314 (1992)), perhaps reflecting a failure of programmed cell death. Mutations of the CD40 ligand cause an X-linked immunodeficiency state characterized by high levels of immunoglobulin M and low levels of immunoglobulin G in plasma, indicating faulty Tcell-dependent B-cell activation (Allen, R.C. et al., Science 259:990 (1993)). Targeted mutations of the low affinity nerve growth factor receptor cause a disorder characterized by faulty sensory innervation of peripheral structures (Lee, K.F. et al, Cell 69:737 (1992)).

35 [0007] TNF and LT-a are capable of binding to two TNF receptors (the 55- and 75-kd TNF receptors). A large number of biological effects elicited by TNF and LT-a, acting through their receptors, include hemorrhagic necrosis of transplanted tumors, cytotoxicity, a role in endotoxic shock, inflammation, immunoregulation, proliferation and anti-viral responses, as well as protection against the deleterious effects of ionizing radiation. TNF and LT-a are involved in the pathogenesis of a wide range of diseases, including endotoxic shock, cerebral malaria, tumors, autoimmune disease, AIDS and graft-host rejection (Beutler, B. and Von Huffel, C., Science 264:667-668 (1994)). Mutations in the p55 Receptor cause increased susceptibility to microbial infection.

40 [0008] Moreover, an about 80 amino acid domain near the C-terminus of TNFR1 (P55) and Fas was reported as the "death domain," which is responsible for transducing signals for programmed cell death (Tartaglia et al., Cell 74:845 (1993)). Other regions of the TNF receptor intracellular domain are responsible for the activation of transcription through NF-kB (Cheng and Baltimore Genes and Development 10:963-973 (1996)). More recent evidence has suggested that receptors may induce signals in cells expressing membrane bound TNF family ligand in a process known as "reverse signaling" (Wiley et al., J. Immunol. 157:3635-3639).

45 [0009] The effects of TNF family ligands and TNF family receptors are varied and influence numerous functions, both normal and abnormal, in the biological processes of the mammalian system. There is a clear need, therefore, for identification and characterization of such receptors and ligands that influence biological activity, both normal and in disease states. In particular, there is a need to isolate and characterize novel members of the TNF receptor family and their ligands.

50 [0010] This indicates that these Tumor necrosis factor receptors (TNF-R) and their ligands have an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further members of Tumor necrosis factor receptor (TNF-R) family and their ligands which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis, and Alzheimers disease.

## SUMMARY OF THE INVENTION

[0011] The present invention relates to tumor necrosis factor receptor (TNF-R) related polypeptides and their ligands, hereinafter referred to as TR1, TR3, TR5, and TL3. The invention also relates to methods to identify agonists and antagonists of TR1, TR3, TR5 and TL3. The agonists and antagonists thus identified can be used to treat chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (eg inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases, cancer (eg lymphoproliferative disorders), atherosclerosis, and Alzheimers disease, among others, caused by imbalance of TR1, TR3, TR5, or TL3.

## DESCRIPTION OF THE INVENTION

[0012] "TR1, or TR1 polypeptide or TR1 protein" refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:1 as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 1; and polypeptides comprising the amino acid sequence which have at least 70% identity to that of SEQ ID NO:1 over its entire length. Furthermore, TR1 also refers to a polypeptide which comprises a sequence which has 70% identity to a fragment of SEQ ID NO: 1. "TR1 or TR1 polypeptide or TR1 protein" also includes derivatives, such as fusion proteins, of the above polypeptides, and some of these derivatives are further illustrated below.

[0013] "TR3 or TR3 polypeptide or TR3 protein" refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 2; and polypeptides comprising the amino acid sequence which have at least 70% identity to that of SEQ ID NO:3 over its entire length. Furthermore, TR3 also refers to a polypeptide which comprises a sequence which has 70% identity to a fragment of SEQ ID NO: 2. "TR3 or TR3 polypeptide or TR3 protein" also includes derivatives, such as fusion proteins, of the above polypeptides, and some of these derivatives are further illustrated below.

[0014] "TR5 or TR5 polypeptide or TR5 protein" refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:3 as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 3; and polypeptides comprising the amino acid sequence which have at least 70% identity to that of SEQ ID NO:3 over its entire length. Furthermore, TR5 also refers to a polypeptide which comprises a sequence which has 70% identity to a fragment of SEQ ID NO: 3. "TR5 or TR5 polypeptide or TR5 protein" also includes derivatives, such as fusion proteins, of the above polypeptides, and some of these derivatives are further illustrated below.

[0015] "TL3 or TL3 polypeptide or TL3 protein" refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:4 as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 4; and polypeptides comprising the amino acid sequence which have at least 70% identity to that of SEQ ID NO:4 over its entire length. Furthermore, TL3 also refers to a polypeptide which comprises a sequence which has 70% identity to a fragment of SEQ ID NO: 4. "TL3 or TL3 polypeptide or TL3 protein" also includes derivatives, such as fusion proteins, of above polypeptides, and some of these derivatives are further illustrated below.

[0016] The cDNA sequence encoding amino acid sequence of SEQ ID NO:4 is contained in SEQ ID NO: 11.

[0017] "Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C.

Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Posttranslational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62.

[0018] "Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. See, e.g.: (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H., and Lipton, D., *SLAM J Applied Math* (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., *SLAM J Applied Math* (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. *et al.*, *J Molec Biol* (1990) 215:403).

[0019] As an illustration, by a polypeptide having an amino acid sequence having at least, for example, 70% "identity" to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to thirty amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 70% identical to a reference amino acid sequence, up to 30% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 30% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

[0020] We have now discovered that TL3 of SEQ ID NO: 4 is a ligand of TR1 of SEQ ID NO:1 (otherwise known as osteoprotegerin (OPG), W.S. Simonet, *et al.*, *Cell*, Vol 89, pp 309-319, 1997). Further, we also discovered that TL3 of SEQ ID NO: 4 is a ligand of TR3 of SEQ ID NO: 2 (otherwise known as DR3). Further, we also discovered that TL3 of SEQ ID NO: 4 is a ligand of TR5 of SEQ ID NO: 3. Thus, the TR1, TR3 and TR5 polypeptides of the present invention, and their ligand, TL3, can be employed in a screening process for compounds which bind to the receptors, or to their ligands, and which activate (agonists) or inhibit activation of (antagonists) TR1, TR3 and TR5 receptor polypeptides of the present invention, or their ligand TL3. Thus, polypeptides of the invention may be used to assess the binding of small molecule substrates, receptors and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates, receptors and ligands may be natural substrates and ligands, or may be structural or functional mimetics. See Coligan *et al.*, *Current Protocols in Immunology* 1(2):Chapter 5 (1991).

[0021] TR1, TR3, TR5, and TL3 polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drugs which stimulate TR1, TR3, TR5, or TL3 on the one hand; and which can inhibit the function of TR1, TR3, TR5, or TL3; or remove TR1, TR3, TR5, or TL3 expressing cells on the other (also defined as antagonists). Antagonists for TR1, TR3, TR5, and TL3 (including agents which remove TR1, TR3, TR5, or TL3 expressing cells) may be employed for a variety of therapeutic and prophylactic purposes for such conditions as chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer (e.g. lymphoproliferative disorders), atherosclerosis, and Alzheimers disease. Agonists can be employed for therapeutic and prophylactic purposes for such conditions responsive to activation of T cells and other components of the immune system, such as for treatment of cancer and AIDS. However, agonists can also be employed for inappropriate stimulation of T cells and other components of the immune system which leads to down modulation of immune activity with therapeutic or prophylactic application for conditions such , as chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, bone diseases, atherosclerosis, and Alzheimers disease.

[0022] Antagonists may be identified using assays to detect compounds which inhibit binding of TL3 to TR1, TR3 or TR5 in either cell-free or cell based assays. Suitable cell-free assays may be readily determined by one of skill in the art. For example, an ELISA format may be used in which purified TR1, TR3 or TR5, or a purified derivative of TR1, TR3 or TR5, such as a fusion protein, containing the extracellular domain of TR1, TR3 or TR5, is immobilized on a suitable surface, either directly or indirectly (e.g., via an antibody to TR1, TR3 or TR5 or to the fused epitope or protein domain)

and candidate compounds are identified by their ability to block binding of purified soluble, extracellular domain of TL3 to TR1, TR3 or TR5. The binding of TL3 to TR1, TR3, or TR5 could be detected by using a label directly or indirectly associated with TL3. Suitable detection systems include the streptavidin horseradish peroxidase conjugate, or direct conjugation by a tag, e.g., fluorescein. Conversely, purified, soluble TL3 may be immobilized on a suitable surface, and candidate compounds identified by their ability to block binding of purified TR1, TR3 or TR5 to TL3. The binding of TR1, TR3 or TR5 to TL3 could be detected by using a label directly or indirectly associated with TR1, TR3 or TR5. Many other assay formats are possible that use the TR1, TR3 or TR5 protein and its ligand.

[0023] Suitable cell based assays may be readily determined by one of skill in the art. In general, such screening procedures involve producing appropriate cells which express the receptor polypeptides (or ligands thereof) of the present invention on the surface thereof. Such cells include cells from mammals, yeast, *Drosophila* or *E. coli*. Cells expressing the receptor, such as TR1, TR3 or TR5, (or cell membrane containing the expressed receptor) are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the receptor is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor, such as the ligand TL3. Alternatively, cells expressing the ligand, such as TL3, (or cell membrane containing the expressed ligand) are then contacted with a receptor, such as TR1, TR3 or TR5, or test compound to observe binding, or stimulation or inhibition of a functional response. Similarly, the assays may simply test binding of a candidate compound wherein adherence to the cells bearing the ligand is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor, such as the receptors TR1, TR3 and TR5. Further, these assays may test whether the candidate compound results in a signal generated by activation of the receptor (e.g. TR1, TR3 or TR5) or its respective ligand (e.g. TL3) using detection systems appropriate to the cells bearing the receptor or its ligand and fusion proteins thereof at their surfaces. Typical fusion partners include fusing the extracellular domain of the receptor or ligand with the intracellular tyrosine kinase domain of a second receptor. Inhibitors of activation are generally assayed in the presence of an agonist, such as the ligand TL3 for cells expressing TR1, TR3 or TR5 receptors or receptor fusions respectively; or the receptor TR1, TR3 or TR5 with cells expressing TL3 ligands or ligand fusions, and the effect on activation by the agonist by the presence of the candidate compound is observed. Standard methods for conducting such screening assays are well understood in the art.

[0024] Examples of potential TR1, TR3 or TR5 antagonists include antibodies or, in some cases, proteins which are closely related to the ligand of the TR1, TR3 or TR5, e.g., a fragment of the respective ligand TL3, or small molecules which bind to the receptor, or its ligand, but do not elicit a response, so that the activity of the receptor is prevented. Examples of potential TR1, TR3 or TR5 agonists include antibodies that bind to TR1, TR3 or TR5, its respective ligand, such as TL3, or derivatives thereof, and small molecules that bind to TR1, TR3 or TR5. These agonists will elicit a response mimicking all or part of the response induced by contacting the native ligand.

[0025] Since receptors may also invoke signals in cells expressing the membrane TL3, these screens may also yield agonists which mimic the agonist activity of TR1, TR3 or TR5 with membrane TL3. Examples of potential TL3 agonists include antibodies that bind to TL3, its respective receptor, such as TR1, TR3 or TR5, or derivatives thereof, and small molecules that bind to TL3. These agonists will elicit a response mimicking all or part of the response induced by contacting the native ligand. Alternatively, TR1, TR3 or TR5 may be expressed as a soluble protein, including versions which fuse all or part of TR1, TR3 or TR5 with a convenient partner peptide for which detection reagents are available, eg TR1-IgG, TR3-IgG or TR5-IgG fusions, and used in a solid state or solution phase binding assay. For example, the soluble TR1, TR3 or TR5 can be used to detect agonist or antagonist binding directly through changes that can be detected experimentally, eg surface plasmon resonance, nuclear magnetic resonance spectrometry, sedimentation, calorimetry. The soluble TR1, TR3 or TR5 can be used to detect agonist or antagonist binding indirectly by looking for competition of the candidate agonist or antagonist with a ligand, such as TL3, whose binding can be detected. Ligand detection methods include antibody recognition, modification of the ligand via radioactive labeling, chemical modification (eg biotinylation), fusion to an epitope tag. Methods include ELISA based assays, immunoprecipitation and scintillation proximity. Assays similar to those described above using soluble or membrane bound TR1, TR3 or TR5 may also be used to identify and purify additional natural ligand(s) of TR1, TR3 or TR5. These ligands may be agonists or antagonists of the receptor

[0026] Thus the invention relates to:

I. A method for identifying agonists or antagonists to TR1, TR3 or TR5 comprising:

- (a) contacting a candidate compound with TR1, TR3 or TR5 in the presence of labeled or unlabeled ligand TL3 respectively; and
- (b) assessing the ability of said candidate compound to compete with TL3 binding to TR1, TR3 or TR5 respectively;

II. The method of I in which TR1, TR3 or TR5 is on the surface of a host cell, on a cell membrane or on a solid support;

III. The method of II for identifying agonists which further includes determining whether the candidate compound affects a signal generated by TR1, TR3 or TR5 polypeptide at the surface of the cell, wherein a candidate compound which increases production of said signal is identified as an agonist;

IV. An agonist identified by the method of I, II or III;

V. The method of II for identifying antagonists which further includes determining whether the candidate compound affects a signal generated by TR1, TR3 or TR5 polypeptide at the surface of the cell, wherein a candidate compound which diminishes production of said signal is identified as an antagonist;

VI. An antagonist identified by the method of I, II or V;

VII. A method for identifying agonists or antagonists to TL3 comprising:

(a) contacting a candidate compound with TL3 in the presence of labeled or unlabeled TR1, TR3 or TR5 respectively; and

(b) assessing the ability of said candidate compound to compete with TR1, TR3 or TR5 binding to TL3;

VIII. The method of VII in which TL3 is on the surface of a host cell, on a cell membrane or on a solid support;

IX. The method of VIII for identifying agonists to TL3 which includes determining whether the candidate compound affects a signal generated by TL3 polypeptide at the surface of the cell, wherein a candidate compound which increases production of said signal is identified as an agonist;

X. An agonist identified by the method of IX;

XI. The method of VIII for identifying antagonists which further includes determining whether the candidate compound affects a signal generated by TL3 polypeptide at the surface of the cell, wherein a candidate compound which diminishes production of said signal is identified as an antagonist; and

XII. An antagonist identified by the method XI

[0027] Thus in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for TR1, TR3, TR5, or TL3 polypeptides; which comprises:

(a) a TR1, TR3, TR5, or TL3 polypeptide, preferably that of SEQ ID NO:1, 2, 3 or 4;

(b) a recombinant cell expressing a TR1, TR3, TR5, or TL3 polypeptide, preferably that of SEQ ID NO: 1, 2, 3 or 4;

(c) a cell membrane expressing a TR1, TR3, TR5, or TL3 polypeptide; preferably that of SEQ ID NO: 1, 2, 3 or 4; or

(d) antibody to a TR1, TR3, TR5, or TL3 polypeptide, preferably that of SEQ ID NO: 1, 2, 3 or 4.

[0028] It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

#### Prophylactic and Therapeutic Methods

[0029] This invention provides methods of treating an abnormal conditions related to both an excess of and insufficient amounts of TR1, TR3, TR5, or TL3 polypeptide activity.

[0030] If the activity of TR1, TR3, TR5, or TL3 polypeptide is in excess, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit activation by blocking binding of ligands to the TR1, TR3 or TR5 polypeptide, or by inhibiting a second signal, and thereby alleviating the abnormal condition.

[0031] In another approach, soluble forms of TR1, TR3 or TR5 polypeptides still capable of binding the ligand in competition with endogenous TR1, TR3 or TR5 polypeptide may be administered. Typical embodiments of such competitors comprise fragments of the TR1, TR3 or TR5 polypeptide.

[0032] For treating abnormal conditions related to an under-expression of TR1, TR3, TR5, or TL3 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates TR1, TR3, TR5, or TL3 polypeptide, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition.

#### Formulation and Administration

[0033] Agonists and antagonists of TR1, TR3, TR5, or TL3 may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and

is well within the skill of the art. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

[0034] Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

5 [0035] Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or  
10 localized, in the form of salves, pastes, gels and the like.

[0036] The dosage range required depends on the choice of peptide or compound, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous  
15 injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

[0037] The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples illustrate, but do not limit the invention.

20

## EXAMPLES

[0038] The expression and determination of receptor ligand pairings for TL3, TR1, TR3 and TR5 are described below. TR1 is also known as osteoprotegerin (Simonet et al., Cell 89:309-319 (1997)). TR3 is also known as DR3, Apo3 or WSL-1 or LARD (Chinnaiyan, A.M. et al., Science 274:990-992 (1996); Marsters, S.A. et al., Curr. Biol. 6:1669-1676 (1996); Kitson, J. et al. Nature 384:372-375 (1996); Screaton, G.R. Proc. Natl. Acad. Sci. USA 94:4615-4619 (1997)). TR5 is also known as TRID or DcR1 (Pan, G. et al., Science 277:815-818 (1997); Sheridan et al., Science 277:818-820 (1997)).

## 30 Expression

[0039] TR1, TR3 and TR5 were expressed as fusion proteins in which the extracellular domain of either receptor was fused at its amino terminus with the hinge-CH2-CH3 region of human IgG1. The junction between the two protein domains was engineered to include the amino acid sequence for proteolytic cleavage by Factor Xa. When expressed  
35 in this form in mammalian cells, the TR fusion proteins (TR1Fc, TR3Fc and TR5 Fc respectively) were secreted as dimeric proteins, and were purified by protein A or protein G sepharose. The non-fused soluble receptor was generated from the TR1Fc, TR3Fc or TR5Fc fusion by incubation with bovine Factor Xa and was purified away from the Fc portion by repassage over protein A sepharose and pooling of the flow through.

[0040] TL3 is a type II membrane proteins in which it is the C-terminus which is extracellular. It was expressed as a secreted fusion protein by engineering an expression DNA construct in which the DNA encoding a substantial part of the carboxyterminal region, which includes all of the residues homologous to mature TNF, was fused to an amino terminal epitope tag sequence, and an amino terminal hydrophobic signal sequence for secretion, detection and purification. When transfected into mammalian cells, these DNA constructs resulted in the secretion of soluble, epitope tagged fusion proteins (sTL3). Specific details of the construction of each expression vector are given below.

45

## TR1

[0041] The sequence of TR1 did not show any transmembrane region by hydrophobicity plot (Goldman et al., (1)). The entire coding region of TR1 minus the terminator codon was therefore used to produce an Fc fusion construct. The TR2 insert in the vector TR2FcLink was replaced with TR1. TR2FcLink encodes amino acids 1-192 of TR2, followed by the amino acids RSIEGRGT for Factor Xa cleavage, followed by residues 226-458 (end) of human IgG1. The IgG1 region also has a mutation of Cys230 to Ala (2). The 3' end of TR1 was amplified from a TR1 cDNA using the following primers: 5' cgc ccc ttg ccc tga cca cta 3' (SEQ ID NO: 5) (upstream of HindIII site) and 5' gcc att tca gat ctt aag cag ctt att ttt act ga 3' (SEQ ID NO: 6) (replaces stop codon with BglII site). The PCR products were cloned into pCR2 (Invitrogen; pCR2TR1) and sequenced. The vector TR2FcLink was digested with EcoRI BglII and calf intestinal phosphatase, then ligated with the EcoRI/HindIII fragment of TR1 cDNA and HindIII/BglII fragment of pCR2TR1 to form TR1FcLink.  
50

[0042] COS cells were transiently transfected with TR1FcLink and the resulting supernatant was immunoprecipitated with protein A agarose. Western blot analysis of the immunoprecipitate using goat anti-human Fc antibodies revealed

a strong band consistent with the expected size for glycosylated TR1Fc.

[0043] CHO cells were transfected with TR2FcLink to produce stable cell lines. Five lines were chosen by dot blot analysis for expansion and were adapted to shake flasks. The line with the highest level of TR2Fc protein expression was chosen by Western blot analysis.

### TR3

[0044] The extracellular domain of TR3 was PCR'd from a full length TR3 cDNA using the following two synthetic oligonucleotide primers: 5' gcc acc atg gaa caa cgc cct aga gga tgt gct gcc gtg gcc gcc gcg ctc ctc ctg gtg ctg ct 3' (SEQ ID NO: 7); 5' tgg acc caa gat ctc tgc ctc cat cca cag aca gc 3' (SEQ ID NO: 8). The PCR product was cloned into pCR2.1 (Invitrogen) and confirmed by sequencing. The EcoRI-BglII fragment of this plasmid was subcloned into the EcoRI-BglII vector fragment of TR2FcLink, replacing the TR2 fragment (see above under TR1 for description of this plasmid) to generate TR3FcLink. TR3FcLink clones were confirmed by restriction enzyme digestion. Transient transfection of clone TR3FcLink into COS cells, followed by immunoprecipitation and Western analysis of the resulting supernatant showed a single band of approximately 55 kD. A similar protein was expressed upon transfection of CHO cells, and was purified by protein G sepharose chromatography.

### TR5

[0045] Two synthetic oligonucleotide primers were used to PCR the extracellular domain of TR5: 5' gcc gcc gag atg caa ggg gtg aag gag 3' (SEQ ID NO: 9) and 5' atg gtg caa gat ctg taa tga gaa gag g 3' (SEQ ID NO: 10). The PCR products were cloned into pCR2.1 (Invitrogen) and sequenced. The EcoRI-BglII fragment of a clone with the expected sequence was subcloned into the EcoRI-BglII vector fragment of TR2FcLink, replacing the TR2 insert, and the product called TR5FcLink. TR5FcLink clones were confirmed by restriction enzyme digestion. Transient transfection of clone TR5FcLink into COS cells, followed by immunoprecipitation and Western analysis of the resulting supernatant showed a band larger than the expected size of 56.6 kD, indicating that the protein is probably glycosylated. Transfection of the same plasmid into CHO cells gave a similar product.

### TL3

[0046] In order to express a soluble form of TL3 protein from CHO cells, a mammalian expression vector was constructed. A cDNA fragment of TL3 protein was created by PCR which started immediately after the putative transmembrane region and ended at the C-terminus. This corresponds to amino acid residues 51 (QQTELQ) to 250 (GFVKL). The gene was tagged at its amino-terminus by an anti-gp120 mAb epitope, followed by 6 His residues and a factor Xa cleavage site (IEGR) for easy detection and purification and generation of the mature untagged protein. BamHI and EcoRV sites were created at ends of the PCR fragment encoding this TL3 fusion protein gene to facilitate its subcloning into the mammalian expression vector pCDTN which contains a tPA leader peptide and CMV promoter. The vector was transfected into both COS cells and CHO cells and the expression of secreted TL3 protein was confirmed by precipitation from cell medium by Ni-NTA and then immunoblotting with a monoclonal antibody to the gp120 epitope peptide attached to the TL3 protein. The protein band of TL3 was seen as ~32 kDa and the calculated molecular weights for TL3 protein is 25 kDa. The difference between the observed and the calculated molecular weight of TL3 protein is likely due to protein glycosylation.

[0047] During large scale expression of TL3 in CHO cells, TL3 was found to be cleaved to a 18 kDa protein. Amino terminal sequencing showed that this protein had lost both epitope tags and 79 N-terminal amino acids resulting in a protein which started at residue (starting amino acids: AVLTKQ). This 18 kDa protein was used for TL3 functional characterization.

### Binding studies

#### Receptor precipitation

[0048] We examined the ability of TR1Fc and TR2Fc to precipitate TL3 in solution followed by detection of the ligand in a western blot using antibodies against the fused epitope tag the ligands or the ligand itself. In a typical experiment, 2ug of TR1Fc or TR2Fc receptor was incubated with 250ng of purified TL3 in binding buffer (25 mM HEPES pH 7.2, 0.1% BSA, 0.01% TWEEN in RPMI 1640). After binding for four hours, receptor complexes were captured on protein A sepharose, centrifuged, washed with binding buffer, electrophoresed on 15% SDS PAGE and transferred for western blotting. TL3 was detected by a 1:5000 dilution of a mouse polyclonal antiserum raised to TL3 expressed and purified from supernatants of CHO cells as described above, and was found to bind to TR1Fc, TR3Fc and TR5Fc but not to other



TNFR related Fc fusion proteins.

[0049] Alternatively, the purified TL3 protein was labeled by I-125 and  $1.5 \times 10^5$  cpm of the labeled TL3 (Final concentration  $\approx 1$  nM) was incubated with 2 ug of each purified protein: TR1-Fc, TR1-Fc (with 10 ug of TR1), TR2-Fc, TR3-Fc and TR6-Fc or COS media containing TR5-Fc at 40C for overnight, followed by protein A-Sepharose precipitation. The pellets was washed and run on 14% SDS-PAGE. The dried gel was exposed to a x-ray film. I-125 labeled TL3 protein was found to be precipitated by TR1-Fc and competed off by excess of TR1 without Fc.

The references cited in this EXAMPLES section are as follows:

1. Engelman-DM; Steitz-TA; Goldman-A. Identifying nonpolar transbilayer helices in amino acid sequences of membrane proteins. Annu-Rev-Biophys-Biophys-Chem. 1986; 15: 321-53.
2. Johanson-K; Appelbaum-E; Doyle-M; Hensley-P; Zhao-B; Abdel-Meguid-SS; Young-P; Cook-R; Carr-S; Matico-R; et-al. Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins. J-Biol-Chem. 1995 Apr 21; 270(16): 9459-71.
3. Kumar-S; Minnich-MD; Young-PR. ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1. J-Biol-Chem. 1995 Nov 17; 270(46): 27905-13.
4. Johnsson, B., Lofas, S. And Lindquist, G. (1991). Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 198:268-277.

# EP 0 911 633 A1

## SEQUENCE LISTING

<110> SmithKline Beecham Corporation

<120> A Method of Identifying Agonist and  
Antagonists For Tumor Necrosis Related  
Receptors TR1, TR3 and TR5

<130> GH50031

<140> Unknown

<141> Herewith

<150> 60/061,334

<151> 1997-10-08

<160> 11

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 401

<212> PRT

<213> Unknown

<400> 1

Met	Asn	Lys	Leu	Leu	Cys	Cys	Ala	Leu	Val	Phe	Leu	Asp	Ile	Ser	Ile
1				5					10					15	
Lys	Trp	Thr	Thr	Gln	Glu	Thr	Phe	Pro	Pro	Lys	Tyr	Leu	His	Tyr	Asp
			20					25					30		
Glu	Glu	Thr	Ser	His	Gln	Leu	Leu	Cys	Asp	Lys	Cys	Pro	Pro	Gly	Thr
		35				40						45			
Tyr	Leu	Lys	Gln	His	Cys	Thr	Ala	Lys	Trp	Lys	Thr	Val	Cys	Ala	Pro
	50				55					60					
Cys	Pro	Asp	His	Tyr	Tyr	Thr	Asp	Ser	Trp	His	Thr	Ser	Asp	Glu	Cys
65				70					75					80	
Leu	Tyr	Cys	Ser	Pro	Val	Cys	Lys	Glu	Leu	Gln	Tyr	Val	Lys	Gln	Glu
			85					90					95		

EP 0 911 633 A1

	Cys	Asn	Arg	Thr	His	Asn	Arg	Val	Cys	Glu	Cys	Lys	Glu	Gly	Arg	Tyr	
				100					105					110			
5	Leu	Glu	Ile	Glu	Phe	Cys	Leu	Lys	His	Arg	Ser	Cys	Pro	Pro	Gly	Phe	
			115					120					125				
	Gly	Val	Val	Gln	Ala	Gly	Thr	Pro	Glu	Arg	Asn	Thr	Val	Cys	Lys	Arg	
			130				135					140					
10	Cys	Pro	Asp	Gly	Phe	Phe	Ser	Asn	Glu	Thr	Ser	Ser	Lys	Ala	Pro	Cys	
	145					150					155					160	
	Arg	Lys	His	Thr	Asn	Cys	Ser	Val	Phe	Gly	Leu	Leu	Leu	Thr	Gln	Lys	
					165					170					175		
15	Gly	Asn	Ala	Thr	His	Asp	Asn	Ile	Cys	Ser	Gly	Asn	Ser	Glu	Ser	Thr	
				180					185					190			
	Gln	Lys	Cys	Gly	Ile	Asp	Val	Thr	Leu	Cys	Glu	Glu	Ala	Phe	Phe	Arg	
			195					200					205				
20	Phe	Ala	Val	Pro	Thr	Lys	Phe	Thr	Pro	Asn	Trp	Leu	Ser	Val	Leu	Val	
			210				215					220					
	Asp	Asn	Leu	Pro	Gly	Thr	Lys	Val	Asn	Ala	Glu	Ser	Val	Glu	Arg	Ile	
	225					230					235					240	
25	Lys	Arg	Gln	His	Ser	Ser	Gln	Glu	Gln	Thr	Phe	Gln	Leu	Leu	Lys	Leu	
					245					250					255		
	Trp	Lys	His	Gln	Asn	Lys	Asp	Gln	Asp	Ile	Val	Lys	Lys	Ile	Ile	Gln	
				260					265					270			
30	Asp	Ile	Asp	Leu	Cys	Glu	Asn	Ser	Val	Gln	Arg	His	Ile	Gly	His	Ala	
			275					280					285				
	Asn	Leu	Thr	Phe	Glu	Gln	Leu	Arg	Ser	Leu	Met	Glu	Ser	Leu	Pro	Gly	
35			290				295					300					
	Lys	Lys	Val	Gly	Ala	Glu	Asp	Ile	Glu	Lys	Thr	Ile	Lys	Ala	Cys	Lys	
	305					310					315					320	
	Pro	Ser	Asp	Gln	Ile	Leu	Lys	Leu	Leu	Ser	Leu	Trp	Arg	Ile	Lys	Asn	
40					325					330					335		
	Gly	Asp	Gln	Asp	Thr	Leu	Lys	Gly	Leu	Met	His	Ala	Leu	Lys	His	Ser	
				340					345					350			
45	Lys	Thr	Tyr	His	Phe	Pro	Lys	Thr	Val	Thr	Gln	Ser	Leu	Lys	Lys	Thr	
			355					360					365				
	Ile	Arg	Phe	Leu	His	Ser	Phe	Thr	Met	Tyr	Lys	Leu	Tyr	Gln	Lys	Leu	
			370				375					380					
50	Phe	Leu	Glu	Met	Ile	Gly	Asn	Gln	Val	Gln	Ser	Val	Lys	Ile	Ser	Cys	
	385					390					395					400	

55

EP 0 911 633 A1

Leu

5

<210> 2

<211> 417

<212> PRT

10

<213> Unknown

<400> 2

15

Met Glu Gln Arg Pro Arg Gly Cys Ala Ala Val Ala Ala Ala Leu Leu

1 5 10 15

Leu Val Leu Leu Gly Ala Arg Ala Gln Gly Gly Thr Arg Ser Pro Arg

20 25 30

20

Cys Asp Cys Ala Gly Asp Phe His Lys Lys Ile Gly Leu Phe Cys Cys

35 40 45

Arg Gly Cys Pro Ala Gly His Tyr Leu Lys Ala Pro Cys Thr Glu Pro

50 55 60

25

Cys Gly Asn Ser Thr Cys Leu Val Cys Pro Gln Asp Thr Phe Leu Ala

65 70 75 80

Trp Glu Asn His His Asn Ser Glu Cys Ala Arg Cys Gln Ala Cys Asp

85 90 95

30

Glu Gln Ala Ser Gln Val Ala Leu Glu Asn Cys Ser Ala Val Ala Asp

100 105 110

Thr Arg Cys Gly Cys Lys Pro Gly Trp Phe Val Glu Cys Gln Val Ser

115 120 125

35

Gln Cys Val Ser Ser Ser Pro Phe Tyr Cys Gln Pro Cys Leu Asp Cys

130 135 140

Gly Ala Leu His Arg His Thr Arg Leu Leu Cys Ser Arg Arg Asp Thr

145 150 155 160

40

Asp Cys Gly Thr Cys Leu Pro Gly Phe Tyr Glu His Gly Asp Gly Cys

165 170 175

Val Ser Cys Pro Thr Ser Thr Leu Gly Ser Cys Pro Glu Arg Cys Ala

180 185 190

45

Ala Val Cys Gly Trp Arg Gln Met Phe Trp Val Gln Val Leu Leu Ala

195 200 205

Gly Leu Val Val Pro Leu Leu Leu Gly Ala Thr Leu Thr Tyr Thr Tyr

210 215 220

50

Arg His Cys Trp Pro His Lys Pro Leu Val Thr Ala Asp Glu Ala Gly

225 230 235 240

55

EP 0 911 633 A1

Met Glu Ala Leu Thr Pro Pro Pro Ala Thr His Leu Ser Pro Leu Asp  
245 250 255  
5 Ser Ala His Thr Leu Leu Ala Pro Pro Asp Ser Ser Glu Lys Ile Cys  
260 265 270  
Thr Val Gln Leu Val Gly Asn Ser Trp Thr Pro Gly Tyr Pro Glu Thr  
275 280 285  
10 Gln Glu Ala Leu Cys Pro Gln Val Thr Trp Ser Trp Asp Gln Leu Pro  
290 295 300  
Ser Arg Ala Leu Gly Pro Ala Ala Ala Pro Thr Leu Ser Pro Glu Ser  
305 310 315 320  
15 Pro Ala Gly Ser Pro Ala Met Met Leu Gln Pro Gly Pro Gln Leu Tyr  
325 330 335  
Asp Val Met Asp Ala Val Pro Ala Arg Arg Trp Lys Glu Phe Val Arg  
340 345 350  
20 Thr Leu Gly Leu Arg Glu Ala Glu Ile Glu Ala Val Glu Val Glu Ile  
355 360 365  
Gly Arg Phe Arg Asp Gln Gln Tyr Glu Met Leu Lys Arg Trp Arg Gln  
370 375 380  
25 Gln Gln Pro Ala Gly Leu Gly Ala Val Tyr Ala Ala Leu Glu Arg Met  
385 390 395 400  
Gly Leu Asp Gly Cys Val Glu Asp Leu Arg Ser Arg Leu Gln Arg Gly  
30 405 410 415  
Pro  
35 <210> 3  
<211> 299  
<212> PRT  
<213> Unknown  
40  
<400> 3  
Met Gln Gly Val Lys Glu Arg Phe Leu Pro Leu Gly Asn Ser Gly Asp  
1 5 10 15  
45 Arg Ala Pro Arg Pro Pro Asp Gly Arg Gly Arg Val Arg Pro Arg Thr  
20 25 30  
Gln Asp Gly Val Gly Asn His Thr Met Ala Arg Ile Pro Lys Thr Leu  
35 40 45  
50 Lys Phe Val Val Val Ile Val Ala Val Leu Leu Pro Val Leu Ala Tyr  
50 55 60  
55

EP 0 911 633 A1

5 Ser Ala Thr Thr Ala Arg Gln Glu Glu Val Pro Gln Gln Thr Val Ala  
 65 70 75 80  
 Pro Gln Gln Gln Arg His Ser Phe Lys Gly Glu Glu Cys Pro Ala Gly  
 85 90 95  
 10 Ser His Arg Ser Glu His Thr Gly Ala Cys Asn Pro Cys Thr Glu Gly  
 100 105 110  
 Val Asp Tyr Thr Asn Ala Ser Asn Asn Glu Pro Ser Cys Phe Pro Cys  
 115 120 125  
 15 Thr Val Cys Lys Ser Asp Gln Lys His Lys Ser Ser Cys Thr Met Thr  
 130 135 140  
 Arg Asp Thr Val Cys Gln Cys Lys Glu Gly Thr Phe Arg Asn Glu Asn  
 145 150 155 160  
 20 Ser Pro Glu Met Cys Arg Lys Cys Ser Arg Cys Pro Ser Gly Glu Val  
 165 170 175  
 Gln Val Ser Asn Cys Thr Ser Trp Asp Asp Ile Gln Cys Val Glu Glu  
 180 185 190  
 25 Phe Gly Ala Asn Ala Thr Val Glu Thr Pro Ala Ala Glu Glu Thr Met  
 195 200 205  
 Asn Thr Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Asn  
 210 215 220  
 30 Thr Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr  
 225 230 235 240  
 Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr Ser  
 245 250 255  
 35 Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr Ser Pro  
 260 265 270  
 Gly Thr Pro Ala Ser Ser His Tyr Leu Ser Cys Thr Ile Val Gly Ile  
 275 280 285  
 40 Ile Val Leu Ile Val Leu Leu Ile Val Phe Val  
 290 295  
 <210> 4  
 45 <211> 250  
 <212> PRT  
 <213> Unknown  
 50 <400> 4  
 Met Pro Ala Ser Ser Pro Phe Leu Leu Ala Pro Lys Gly Pro Pro Gly  
 55

EP 0 911 633 A1

	1		5		10		15									
	Asn	Met	Gly	Gly	Pro	Val	Arg	Glu	Pro	Ala	Leu	Ser	Val	Ala	Leu	Trp
5			20					25						30		
	Leu	Ser	Trp	Gly	Ala	Ala	Leu	Gly	Ala	Val	Ala	Cys	Ala	Met	Ala	Leu
			35					40						45		
	Leu	Thr	Gln	Gln	Thr	Glu	Leu	Gln	Ser	Leu	Arg	Arg	Glu	Val	Ser	Arg
10			50					55						60		
	Leu	Gln	Arg	Thr	Gly	Gly	Pro	Ser	Gln	Asn	Gly	Glu	Gly	Tyr	Pro	Trp
	65						70					75				80
	Gln	Ser	Leu	Pro	Glu	Gln	Ser	Ser	Asp	Ala	Leu	Glu	Ala	Trp	Glu	Asn
15					85					90					95	
	Gly	Glu	Arg	Ser	Arg	Lys	Arg	Arg	Ala	Val	Leu	Thr	Gln	Lys	Gln	Lys
					100					105					110	
	Lys	Gln	His	Ser	Val	Leu	His	Leu	Val	Pro	Ile	Asn	Ala	Thr	Ser	Lys
20			115							120					125	
	Asp	Asp	Ser	Asp	Val	Thr	Glu	Val	Met	Trp	Gln	Pro	Ala	Leu	Arg	Arg
			130						135					140		
	Gly	Arg	Gly	Leu	Gln	Ala	Gln	Gly	Tyr	Gly	Val	Arg	Ile	Gln	Asp	Ala
25			145				150					155				160
	Gly	Val	Tyr	Leu	Leu	Tyr	Ser	Gln	Val	Leu	Phe	Gln	Asp	Val	Thr	Phe
					165					170					175	
	Thr	Met	Gly	Gln	Val	Val	Ser	Arg	Glu	Gly	Gln	Gly	Arg	Gln	Glu	Thr
30					180					185					190	
	Leu	Phe	Arg	Cys	Ile	Arg	Ser	Met	Pro	Ser	His	Pro	Asp	Arg	Ala	Tyr
			195						200						205	
	Asn	Ser	Cys	Tyr	Ser	Ala	Gly	Val	Phe	His	Leu	His	Gln	Gly	Asp	Ile
35			210					215					220			
	Leu	Ser	Val	Ile	Ile	Pro	Arg	Ala	Arg	Ala	Lys	Leu	Asn	Leu	Ser	Pro
	225					230					235					240
40	His	Gly	Thr	Phe	Leu	Gly	Phe	Val	Lys	Leu						
					245					250						

45	<210>	5
	<211>	21
	<212>	RNA
	<213>	Unknown
50	<400>	5

55

cgcccccttgc cctgaccact a  
21

5

<210> 6  
<211> 35  
10 <212> RNA  
<213> Unknown

<400> 6  
15 gccatttcag atcttaagca gcttattttt actga  
35

<210> 7  
20 <211> 65  
<212> RNA  
<213> Unknown

25 <400> 7  
gccaccatgg aacaacgccc tagaggatgt gctgccgtgg ccgccgcgct cctcctggtg  
60  
30 ctgct  
65

<210> 8  
35 <211> 35  
<212> RNA  
<213> Unknown

40 <400> 8  
tggacccaag atctctgcct ccattccacag acagc  
35

45 <210> 9  
<211> 27  
<212> RNA  
50 <213> Unknown

<400> 9  
55



EP 0 911 633 A1

gccgccgaga tgcaaggggt gaaggag  
27

5

<210> 10  
<211> 28  
<212> RNA  
10 <213> Unknown

<400> 10  
atggtgcaag atctgtaatg agaagagg  
15 28

<210> 11  
<211> 1717  
20 <212> PRT  
<213> Unknown

<400> 11

25	acctctgtcc ttagagggga ctggaaccta attctcctga gcctgagggg gggaggagg	60
	tctcaagaca acgctgtccc cacgacggag tgccaggagc actaacagta cccttagatt	120
	gctttcctcc tccctccttt tttattttca agttcctttt tatttctcct tgcgtaacaa	180
	cctttctccc ttctgcacca ctgcccgtac ccttaccgc gccgccacct ccttgctaca	240
	ccactcttga aaccacagct gttggcaggg tccccagct catgccagcc tcatctcctt	300
30	tcttgctagc ccccaaaggg cctccaggca acatgggggg cccagtcaga gagccggcac	360
	tctcagttgc cctctggttg agttgggggg cagctctggg ggccgtggct tgtgccatgg	420
	ctctgctgac ccaacaaaca gagctgcaga gcctcaggag agaggtgagc cggtgcaga	480
	ggacaggagg cccctcccag aatggggaag ggtatccctg gcagagtctc ccggagcaga	540
35	gttccgatgc cctggaagcc tgggagaatg gggagagatc ccggaaaagg agagcagtg	600
	tcacccaaaa acagaagaag cagcactctg tcttgcacct ggttccatt aacgccacct	660
	ccaaggatga ctccgatgtg acagagggtga tgtggcaacc agctcttagg cgtgggagag	720
	gcctacaggc ccaaggatat ggtgtccgaa tccaggatgc tggagtatat ctgctgtata	780
40	gccaggctct gtttcaagac gtgactttca ccatgggtca ggtggtgtct cgagaaggcc	840
	aaggaaggca ggagactcta ttccgatgta taagaagtat gccctccac ccggaccggg	900
	cctacaacag ctgctatagc gcagggtgtc tccatttaca ccaaggggat attctgagt	960
	tcataattcc ccgggcaagg gcgaaactta acctctctcc acatggaacc ttcttgggt	1020
45	ttgtgaaact gtgattgtgt tataaaaagt ggctcccagc ttggaagacc agggagggt	1080
	catactggag acagccaaga gctgagtata taaaggagag ggaatgtgca ggaacagagg	1140
	cgtcttctct gggttggctc cccgttctc acttttccct ttctattccc accccctaga	1200
	ctttgatttt acggatatct tgcttctgtt ccccatggag ctccgaattc ttgcgtgtgt	1260
50	gtagatgagg ggcgggggac gggcggcagg cattgtccag acctggtcgg ggccactgg	1320

55

aagcatccag aacagcacca ccatctagcg gccgctctag aggatccctc gaggggcccc 1380  
 agcttacgcg tgcattgcgac gtcattagctc tctccctata gtgagtcgta ttataagcta 1440  
 5 gcttgggatc tttgtgaagg aaccttactt ctgtgggtgtg acataattgg acaaactacc 1500  
 tacagagatt taaagctcta aggtaaatat aaaattttta agtgataat gtgttaaact 1560  
 agctgcata gcttgctgct tgagagtttg gcttactgag tatgattatg aaaatattat 1620  
 acacaggagc tagtgatcta tgttggtttt agatcaagcc aaggtcattc aggcctcagc 1680  
 10 tcaagctgct atgatcatat cagcatacaa ttgtgag 1717

## 15 Claims

1. A method for identifying agonists or antagonists to TR1, TR3 or TR5 comprising:
  - (a) contacting a candidate compound with TR1, TR3 or TR5 in the presence of labeled or unlabeled ligand TL3 respectively; and
  - (b) assessing the ability of said candidate compound to compete with TL3 binding to TR1, TR3 or TR5 respectively.
2. The method of claim 1 in which TR1, TR3 or TR5 is on the surface of a host cell, on a cell membrane or on a solid support.
3. The method of claim 2 for identifying agonists which further includes determining whether the candidate compound affects a signal generated by TR1, TR3 or TR5 polypeptide at the surface of the cell, wherein a candidate compound which increases production of said signal is identified as an agonist.
4. An agonist identified by the method of claim 1, 2 or 3.
5. The method of claim 2 for identifying antagonists which further includes determining whether the candidate compound affects a signal generated by TR1, TR3 or TR5 polypeptide at the surface of the cell, wherein a candidate compound which diminishes production of said signal is identified as an antagonist.
6. An antagonist identified by the method of claim 1, 2, or 5.
7. A method for identifying agonists or antagonists to TL3 comprising:
  - (a) contacting a candidate compound with TL3 in the presence of labeled or unlabeled TR1, TR3 or TR5; and
  - (b) assessing the ability of said candidate compound to compete with TR1, TR3 or TR5 binding to TL3.
8. The method of claim 7 in which TL3 is on the surface of a host cell, on a cell membrane or on a solid support.
9. The method of claim 8 for identifying agonists which further includes determining whether the candidate compound affects a signal generated by TL3 polypeptide at the surface of the cell, wherein a candidate compound which increases production of said signal is identified as an agonist.
10. An agonist identified by the method of claim 7, 8, and 9.
11. The method of claim 8 for identifying antagonists which further includes determining whether the candidate compound affects a signal generated by TL3 polypeptide at the surface of the cell, wherein a candidate compound which diminishes production of said signal is identified as an antagonist.
12. An antagonist identified by the method of claim 11.
13. A method of claim 1 for identifying agonists or antagonists to TR1 comprising:

- (a) contacting a candidate compound with TR1 in the presence of labeled or unlabeled ligand TL3; and
- (b) assessing the ability of said candidate compound to compete with TL3 binding to TR1.

- 5
14. The method of claim 13 in which TR1 is on the surface of a host cell, on a cell membrane or on a solid support.
15. The method of claim 14 for identifying agonists which further includes determining whether the candidate compound affects a signal generated by TR1 polypeptide at the surface of the cell, wherein a candidate compound which increases production of said signal is identified as an agonist.
- 10
16. An agonist identified by the method of claim 13, 14 or 15.
17. The method of claim 14 for identifying antagonists which further includes determining whether the candidate compound affects a signal generated by TR1 polypeptide at the surface of the cell, wherein a candidate compound which diminishes production of said signal is identified as an antagonist.
- 15
18. An antagonist identified by the method of claim 13, 14, or 17.
19. A method of claim 7 for identifying agonists or antagonists to TL3 comprising:
- 20
- (a) contacting a candidate compound with TL3 in the presence of labeled or unlabeled TR1; and
  - (b) assessing the ability of said candidate compound to compete with TR1 binding to TL3.
20. The method of claim 19 in which TL3 is on the surface of a host cell, on a cell membrane or on a solid support.
- 25
21. The method of claim 20 for identifying agonists which further includes determining whether the candidate compound affects a signal generated by TL3 polypeptide at the surface of the cell, wherein a candidate compound which increases production of said signal is identified as an agonist.
22. An agonist identified by the method of claim 19, 20, or 21.
- 30
23. The method of claim 20 for identifying antagonists which further includes determining whether the candidate compound affects a signal generated by TL3 polypeptide at the surface of the cell, wherein a candidate compound which diminishes production of said signal is identified as an antagonist.
- 35
24. An antagonist identified by the method of claim 19, 20 or 23.

40

45

50

55



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 98 20 3332

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
E	WO 99 00518 A (ABBOTT LAB) 7 January 1999  seq. ID NO'S 1 AND 2 * claim 22 *	1-3, 5, 7-9, 11, 13-15, 17, 19-21, 23	G01N33/50 G01N33/566
X	EP 0 308 378 A (YEDA RES & DEV) 22 March 1989  * page 3, line 1 - line 2 * * the whole document *	4, 6, 10, 12, 16, 18, 22, 24	
A		1-24	
P, X	EP 0 867 509 A (SMITHKLINE BEECHAM CORP) 30 September 1998  * claims 23, 25 *	4, 6, 10, 12, 16, 18, 22, 24	
A	WO 97 33902 A (HUMAN GENOME SCIENCES INC ; NI JIAN (US); GENTZ REINER L (US); YU G) 18 September 1997 * claim 30 *	1-24	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			G01N C07K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		12 February 1999	Hoekstra, S
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C07)



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 98 20 3332

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	PAN, G. ET AL.: "An antagonist receptor and a death domain-containing receptor for TRAIL" SCIENCE, vol. 277, 8 August 1997, pages 815-818, XP002093247 ---	1-24	
A	SHERIDAN, J.P. ET AL.: "Control of TRAIL-induced apoptosis by a family of signalling and decoy receptors" SCIENCE, vol. 277, 8 August 1997, pages 818-821, XP002093248 * the whole document *	1-24	
A	GURA, T.: "How TRAIL kills cancer cells, but not normal cells." SCIENCE, vol. 277, 8 August 1997, page 768 XP002093249 * the whole document *	1-24	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
A,D, P	MARSTERS ET AL: "Identification of a ligand for the death domain" CURRENT BIOLOGY, vol. 8, no. 9, 13 April 1998, pages 525-528, XP002093250 * the whole document *	1-24	
A,D, P	HAHNE, M. ET AL.: "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth." J. EXP. MED., vol. 188, 21 September 1998, pages 1185-1190, XP002093251 * the whole document *	1-24	



European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number

EP 98 20 3332

Claim(s) searched incompletely:  
4,6,10,12,16,18,22,24

Reason for the limitation of the search:

The subject-matter of claims 4,6,10,12,16,18,22,24 relate to products per se. These products are not characterised by technical features of the compounds themselves. Absent of any such technical features these claims are considered not to meet the prescribed requirements of Article 6 and Rule 6.3(a) PCT to such an extend that a meaningful search is not possible. Moreover, the conceivable compounds of the prior art could not be tested by the ISA for being an agonist or antagonist. The search report nevertheless cites documents for these claims from which fortuitously disclosed qualifications of a compound to be an agonist or antagonist for the indicated receptors happens to be derivable.

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 20 3332

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-02-1999

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9900518	A	07-01-1999	NONE		
EP 0308378	A	22-03-1989	IL	83878 A	31-07-1995
			AT	114715 T	15-12-1994
			AU	2206888 A	16-03-1989
			DE	3852255 D	12-01-1995
			DE	3852255 T	18-05-1995
			ES	2067486 T	01-04-1995
			GR	3014976 T	31-05-1995
			JP	2000200 A	05-01-1990
			JP	2755394 B	20-05-1998
			JP	9118631 A	06-05-1997
			US	5695953 A	09-12-1997
			US	5512544 A	30-04-1996
EP 0867509	A	30-09-1998	CA	2221687 A	05-08-1998
			JP	10313874 A	02-12-1998
WO 9733902	A	18-09-1997	AU	5366596 A	01-10-1997